Ximelagatran/MelagatranA Review of its Use in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

[1] Agnelli G(2002)Unresolved issues in the prevention and treatment of venous thromboenibolism Semin Thromb Hemost 28 33-40

[2] Arnold DM(2001)Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines Chest 120 1964-71

[3] Kahn SR(2001)Prevention of venous thromboembolism Chest 119 132S-75S

[4] Shrier I(2002)Diagnosis and treatment of venous thromboembolism Annu Rev Med 53 15-33

[5] Geerts WH(1998)Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes Thromb Haemost 79 110-8

[6] Heit JA(2003)Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans Drug Metab Dispos 31 294-305

[7] Clagett GP(2001)Melagatran and ximelagatran: anticoagulant, thrombin inhibitor Drugs Future 26 1155-70

[8] Lee AYY(2003)The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review Thromb Res 109 S9-15

[9] Hirsh J(1999)Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT Thromb Haemost 81 358-63

[10] Gustafsson D(2003)Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects Eur J Clin Pharmacol 59 35-43

[1] Agnelli G(2002)Unresolved issues in the prevention and treatment of venous thromboenibolism Semin Thromb Hemost 28 33-40

[2] Arnold DM(2001)Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines Chest 120 1964-71

[3] Kahn SR(2001)Prevention of venous thromboembolism Chest 119 132S-75S

[4] Shrier I(2002)Diagnosis and treatment of venous thromboembolism Annu Rev Med 53 15-33

[5] Geerts WH(1998)Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes Thromb Haemost 79 110-8

[6] Heit JA(2003)Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans Drug Metab Dispos 31 294-305

[7] Clagett GP(2001)Melagatran and ximelagatran: anticoagulant, thrombin inhibitor Drugs Future 26 1155-70

[8] Lee AYY(2003)The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review Thromb Res 109 S9-15

[9] Hirsh J(1999)Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT Thromb Haemost 81 358-63

[10] Gustafsson D(2003)Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects Eur J Clin Pharmacol 59 35-43